Abstract
A 61-year-old man with pulmonary and bone metastases from a primary transitional cell carcinoma of the prostate (TCCP) refractory to MVAC was treated with mitoxantrone 16 mg/m2 i.v. at 3-week intervals. With this, he experienced an objective partial remission lasting 5 months and a significant decrease in cancer-related symptoms. Mitoxantrone deserves further evaluation in this rare disease.
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary
-
Carcinoma, Transitional Cell / drug therapy
-
Carcinoma, Transitional Cell / secondary*
-
Cisplatin / administration & dosage
-
Disease Progression
-
Doxorubicin / administration & dosage
-
Fatal Outcome
-
Follow-Up Studies
-
Humans
-
Injections, Intravenous
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Mitoxantrone / therapeutic use*
-
Prostatic Neoplasms / drug therapy*
-
Remission Induction
-
Vinblastine / administration & dosage
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Vinblastine
-
Doxorubicin
-
Mitoxantrone
-
Cisplatin
-
Methotrexate